Cancer Research UK Centre for Drug Development

Cancer Research UK's Centre for Drug Development is the partner of choice for early-phase cancer drug development. Through clinical development collaborations with Cancer Research Horizons, the academic and biopharma sectors across the globe can access its unique infrastructure to realise the full potential of their research.

Scientist working in a lab looking at a test tube.

>30

years of experience

~20

agents under active development

6

agents registered as medicines to date

Why work with the Centre for Drug Development?

With a team of over 100 drug development scientists and operational staff, their expertise spans preclinical and medical sciences, regulatory affairs, quality assurance, project management, drug safety, clinical operations and data management.

Their goal is to see scientific breakthroughs bring benefits to patients sooner. Priority targets include:

First-in-class therapies
First-in-human clinical trials

Find out more

News from the Centre for Drug Development

Hundreds of cancer patients to benefit from improved access to genetic testing

Cancer Research UK, The Royal Marsden and Guardant Health will make hundreds of genetic tests available to provide personalised cancer care across the UK.

UCB, Cancer Research UK and Cancer Research Horizons announce new strategic alliance to accelerate development of novel cancer therapies

This alliance expands on the successful multi-project collaboration between UCB and Cancer Research UK’s Centre for Drug Development.

Cancer Research UK and NovalGen dose the first patient in the Phase 1 trial of T-cell engager NVG-222

Cancer Research UK and NovalGen have dosed the first patient in a Phase 1 trial of NVG-222 for ROR1-positive blood cancers. NVG-222 is a bispecific T-cell engager (ROR1 × CD3) using NovalGen’s AutoRegulation technology to improve safety and sustain T-cell activity. The UK trial, led at University College London Hospitals NHS Foundation Trust, will enrol patients nationwide and uses an adaptive design to evaluate dosing, treatment strategy and biomarkers.